AR and prostate cancer: Early stage prostate cancers primarily express the full-length, 110 kDa version of the AR (also known as AR-FL), while AR-V7 and other AR variants have been detected within advanced prostate cancers and tumors that have developed resistance to androgen-deprivation therapy or antiandrogens [37].